EUCTR2020-003770-50-CZ进行中（未招募）1 期
An Open-Label, Single/Multiple Ascending Dose Study to Assess the Pharmacokinetics, Efficacy, Safety and Tolerability of Inhalation Delivery of Hydroxychloroquine Sulfate (HCQ) in Healthy Volunteers and patients with COVID-19
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 137
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria healthy subjects
- •1.Healthy male volunteers = 18 and = 55 years old (date of ICF signature is decisive).
- •2.Non-smoker or past-smoker (who has stopped smoking at least 6 months before the first dosing).
- •3.Body Mass Index at screening = 18.5 and = 30.0 kg/m2.
- •4.Subject is available for the whole study and has provided his written informed consent.
- •5.With clinical history and physical examination results within normality.
- •6.All laboratory screening results within the normal range or deemed clinically insignificant by Investigator.
- •7.Acceptance of use of effective contraceptive measures during the whole study.
- •8.Screening Vital signs and ECG without significant deviations.
- •9.Czech citizenship.
- •Inclusion criteria COVID-19 patients
- •1.Study subjects must be =18 years inclusive (male or female)
- •2.Hospitalized or admitted patients to hospital with COVID-19 pneumonia or respiratory symptoms confirmed with positive PCR or antigen test for SARS-CoV-2 virus
- •3.Moderate to severe disease with or without supplemental oxygen administration by nasal cannula, face mask and or noninvasive or mechanical ventilation (for the purpose of the study the patient conditions and treatment will be considered, please see the protocol section Study population specific information and procedures) etc
- •4.Capable of giving sSigned informed consent prior to performing study procedures (please see the protocol section Study population specific information and procedures)
- •5.For woman of childbearing potential use of contraceptive measures during the study up to follow-up call day 30 after the end of treatment and or later discharge from the hospital
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 137
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria healthy subjects
- •1.Known hypersensitivity to 4-aminoquinoline compounds and contraindication of HCQ use.
- •2.Medical history of retinal or visual field changes of any etiology.
- •3.Acute or chronic diseases and/or clinical findings e.g. several renal or liver impairment, which may interfere with the aims of the study or with the bioavailability and/or pharmacokinetics of the IMP.
- •4.Medical history of asthma bronchiale or bronchospasms or any allergies deemed clinically significant by Investigator.
- •5.Clinically significant illness within 4 weeks before the first dosing, including major surgery.
- •6.Vaccination with live vaccines less than 14 days prior to the first administration of IMP.
- •7.Use of an investigational drug within 2 months prior to dosing in this study.
- •8.Use of HCQ within 3 months prior to dosing in this study.
- •9.Any clinically significant laboratory abnormality, including positive results of HBsAg and/or HCV and/or HIV test during screening procedure.
- •10.Prolonged QT interval at baseline or at increased risk for arrhythmia.
- •11.Positive alcohol breath test.
- •12.Positive urinary drug screen test at check-in.
- •13.Serious mental disease or inability to cooperate with clinical team.
- •14.Sitting blood pressure is out of the range of 90 - 140 mmHg for systolic BP and/or 60-90 mmHg for diastolic BP and/or heart rate out of the range of 50-100 bpm at screening.
- •15.Body temperature <35.7 and/or >37.2°C at screening or baseline.
- •16.History of substance abuse including alcohol.
- •17.Donation or loss of = 500 mL of blood within 90 days prior to the first dosing.
- •18.Donation of plasma or platelets within 14 days prior to the first dosing.
- •19.Haemoglobin below 120 g/L for women and 130 g/L for men at Screening.
- •20.Leukocytosis, level of leukocytes above 9.00 * 109/L at Screening.
- •21.All prescription, over-the-counter and herbal medications are prohibited within 10 days prior to study dosing (with exception of paracetamol =1000 mg/day at the discretion of the Investigator).
- •22.Subject is not willing to keep contraceptive requirements (set in Inclusion criteria).
- •23. Employees of the Study Centers, Study personnel and relatives of study personnel
- •Exclusion Criteria COVID-19 patients
- •1.Presence of retinal or visual field changes of any etiology
- •2.Known hypersensitivity to 4-aminoquinoline compounds and contraindication of HCQ or present peroral HCQ use
- •3.Prolonged QT interval at baseline or at increased risk for arrythmia
- •4.Use of HCQ contraindicated medications (e.g. citalopram)
- •5.Multi-organ system dysfunction as judged by the investigator to be of clinical relevance
- •6.Elevated liver enzymes or judged by the investigator to be of clinical relevance
- •7.Exclusion of patients with hypokalemia/hypomagnesemia
- •8.Sever renal impairment as judged by the investigator to be of clinical relevance
- •9. Medical history of asthma bronchiale or bronchospasms or any allergies deemed clinically significant by Investigator
- •10.Participation of study subject in any concurrently ongoing clinical investigation for COVID-19 treatment which could interfere with the study outcome
- •11.Pregnancy and breast feeding.
- •12.Employees of the Study Centers, Study personnel and relatives of study personnel
研究者
相似试验
终止
1 期
Safety, tolerability and pharmacokinetics of extended release formulations of ATN-249 in healthy volunteers when dosed once a day or over several daysInflammatory and Immune System - Normal development and function of the immune systemHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersCardiovascular - Other cardiovascular diseasesSkin - Other skin conditionsHereditary AngioedemaACTRN12618001417279ifeSci Pharmaceuticals, inc.6
招募中
不适用
Open label, Single Ascending Dose, Cross-over Study to Assess the Pharmacokinetics of Circadin® (Prolonged-Release Melatonin) Mini tablets in Children with Neurodevelopmental disorders and Sleep Disturbances.Sleep disorderssleep disoderInsomniaNL-OMON39955eurim Pharmaceuticals Ltd.16
进行中（未招募）
1 期
A Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant RecipientsPrevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000004865EUCTR2019-001730-34-GBSangamo Therapeutics France SAS30
进行中（未招募）
1 期
A Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant RecipientsEUCTR2019-001730-34-DESangamo Therapeutics France SAS60
招募中
2 期
A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients.Allograft rejection1002766510029149Renal transplant rejectionNL-OMON56213Sangamo Therapeutics France SAS8